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Familial  clustering  of osteosarcoma suggests  the  involvement  of genetic  factors 
(1, 2), and the demonstration of a  high incidence of osteosarcoma-specific antibodies 
(3,  4),  as  well  as  tumor-specific cell-mediated  immunity  (5)  in  patients  and  their 
relatives,  indicates the involvement of immunological factors in the pathogenesis of 
this disease.  Certain  Gm allotypes  (genetic markers of IgG) have been shown to be 
associated with a high relative risk of  some forms of  cancer. For instance, in Caucasians 
an  unusual Gm haplotype--Gm 1,3;5,13,14--has been found to be associated with 
neuroblastoma  (6),  and  an  increased  frequency  of Gm  (2)  has  been  reported  in 
patients with malignant melanoma (7, 8).  A recent report has shown an association 
of the Gm 1,2;  13,15,16,21  phenotype with lung cancer and primary hepatoma in the 
Japanese  (9). To  our  knowledge,  however,  the  possible  role  of Gm  allotypes  in 
predisposition to osteosarcoma has not been examined. 
Immune responsiveness to a  variety of antigens in both experimental animals and 
humans has been shown to be controlled either by major histocompatibility complex 
(MHC)-linked immune response (Ir)  genes or by allotype-linked Ir genes (10-13). In 
some instances  an  interactive effect of these two unlinked  genetic systems has  been 
observed  (12).  It is possible  that  MHC-linked or allotype-linked Ir genes may also 
influence humoral immunity to tumor antigens. In this report we present evidence for 
complementary Ir  genes  controlling  immune  responses  to  osteosarcoma-associated 
antigens (OSAA). 
Materials and Methods 
Patients.  Blood was collected from 50 Caucasian patients with osteosarcoma at the Medical 
University  of South  Carolina,  Charleston,  SC,  and  the  Veterans  Administration  Medical 
Center, Gainesville, FL. Diagnosis of osteosarcoma was confirmed after examination  of biopsy 
specimens. All patients  had osteoblastic sarcoma. They did  not include  fibroblastic  or chon- 
droblastic  variants. 
Cell Lines.  Osteosarcoma cell lines TE-85 and LM were used. These are biologically proven 
osteosarcoma cell lines by criteria  of immunofluorescence, fine structure  histology, karyotype 
analysis, and enzyme activities  (14, 15). They do not react  with  anti-A,  anti-B,  or anti-AB 
human blood  group antisera,  or with  antisera  for HLA-A,  B, C, and DR antigens.  Several 
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TABLE I 
Distribution of Gm Phenotypes in Osteosarcoma Patients  (n =  50) and 
Normal Controls (n =  906) 
Phenotype 
Incidence 
Osteosarcoma  Normal 
patients  controls 
Gm  1,17;21  6  3 
Gm  1,2,17;21  6  4 
Gm  3;5,13,14  36  47 
Gm  1,3,17;5,13,14,21  44  31 
Gm  1,2,3,17;5,13,14,21  8  14 
TAaLE II 






Gm  1,17;21  0  3  (11) 
Gm  1,2,17;21  1  (4)  2  (7) 
Gm  3,5;13,14  1  (8)  17  (63)* 
Gm  1,3,17;5,13,14,21  19  (83)  3  (11)* 
Gm  1,2,3,17;5,13,14,21  2  (4)  2  (7) 
* P <  0.00001. 
other cell lines  were used as controls: WI-38 (embryonic lung), TE-32  (rhabdomyosarcoma), 
CAMA-1 and SW-527 (breast carcinoma), and M-14 (melanoma). 
Detection of Antibodies to OSAA.  Sera (diluted  1:20) from 50 patients with osteosarcoma were 
assayed for antibodies directed against OSAA by the indirect immunofluorescence test described 
previously (16). Sera showing strong membrane immunofluorescence with TE-85 and LM cells 
were considered positive and those showing no immunofluorescence were considered negative 
for antibodies to OSAA. 
Gm  Allotyping.  Serum  samples  were  typed  for Gm  antigens  l(a),  2(x),  3(f),  5(bl),  6(c3), 
13(b3),  14(b4),  17(z),  and  21(g)  by our standard  hemagglutination  inhibition  method  (17). 
Allotyping and detection of antibodies were done in a double-blind fashion. 
Statistical  Analysis.  Data were analyzed by 2 ×  2 and 2 ×  5 contingency chi-square tests. 
Results 
The  frequencies  of various  Gm  phenotypes  in  osteosarcoma  patients,  compared 
with those previously published  for the normal population  (8)  are shown in Table I. 
Five Gm phenotypes, all commonly found in Caucasians,  were present.  None of the 
phenotypes was significantly associated with osteosarcoma. The distribution of various 
Gm  phenotypes  with  respect  to  the  presence  or absence  of antibodies  to OSAA  is 
shown in Table II. Two Gm phenotypes--Gm 3;5,13,14 and Gm  1,3,17;5,13,14,21- 
were significantly associated with  immune response to OSAA; however, the associa- 
tions for the two phenotypes were in opposite directions. Gm 3;5,13,14 was associated 
with  no  detectable  antibody  (8%  positive  and  63%  negative),  whereas  Gm 
1,3,17;5,13,14,21  was  clearly  associated  with  detectable  antibodies  to  OSAA  (83% 
positive and  11% negative).  Both were highly significant even after correction for the 
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Discussion 
The finding that the distribution of the Gm phenotypes detected in our patient 
population was similar to that in the normal population suggests that Gm allotypes 
are not involved in the pathogenesis ofosteosarcoma, and that if disease susceptibility 
genes for osteosareoma exist, they probably are not in linkage disequilibrium with the 
alleles coding for Gm allotypes. This  does not exclude loose or  moderate  linkage 
between Gm loci and loci controlling the pathogenesis of osteosarcoma, which can be 
determined only after linkage analysis in multiple-case families (18,  19). 
Of the 50 patients tested for the presence of antibodies to OSAA, 23 were positive. 
In an earlier report  (20),  using appropriate control cell lines, we showed that these 
antibodies are specific for OSAA and are of the IgG class;  the anti-OSAA activity of 
the sera  from osteosarcoma patients was  abolished after absorption  with cultured 
human osteosarcoma cells  from line LM, TE-85, or G292, but not after absorption 
with cells from line WI-38 (embryonic lung), TE-32  (rhabdomyosarcoma), CAMA-1 
and SW-527  (breast carcinoma), or M-14  (melanoma). These antibodies apparently 
are not directed toward fetal-type antigens because no membrane immunofluorescence 
was seen with M-14  cells,  which are known to express  fetal-type antigens (21).  In 
addition, TE-85 and LM cells apparently do not express fetal-type antigens (K. Y. 
Tsang, unpublished observation). In the present study we found significant associa- 
tions between Gm  3;5,13,14  and  unresponsiveness to  OSAA  and  between Gm  1,- 
3,17;5,13,14,21  and responsiveness to OSAA. Because the most probable genotype of 
the  Gm  3;5,13,14  phenotype  is  Gm  3;5,13,14/Gm  3;5,13,14  and  that  of  Gm 
1,3,17;5,13,14,21  is  Gm  1,17;21/Gm  3;5,13,14,  our  results  can  be  explained  by 
postulating two  Ir genes in  linkage disequilibrium with  the Gm  1,17;21  and  Gm 
3; 5,13,14 haplotypes, respectively. Possession of either gene alone, i.e., in Gm 1,17; 21 / 
Gm 1,17;21 and Gm 3;5,13,14/Gm 3;5,13,14 homozygotes, would not confer humoral 
responsiveness to OSAA. However, in the heterozygous condition, i.e., Gm  1,17;21/ 
Gm 3;5,13,14, the genes would complement to permit a humoral response to OSAA. 
Existence of complementary Ir genes for several antigens has been  documented in 
experimental animals (10). 
Two  other  explanations  can  also  be  forwarded  to  explain  these  results.  First, 
immune responsiveness to OSAA might be controlled by a single dominant Ir gene, 
Ir(+),  in  linkage disequilibrium  with  the Gm  1,17;21 haplotype and  its  recessive 
allele, Ir(-), in linkage disequilibrium with the Gm 3;5,13,14 haplotype. This would 
explain the association of Gm 3;5,13,14/Gm  3;5,13,14  [Ir(-)/Ir(-)]  with unrespon- 
siveness to OSAA and the association ofGm 1,17;21/Gm 3;5,13,14 [Ir(+)/Ir(-)] with 
responsiveness to OSAA. Alternatively, in addition to Ir genes, immune suppression 
(Is) genes might  be  involved.  An  Is  gene in  linkage disequilibrium  with  the Gm 
3;5,13,14  haplotype  would  explain  the  association  of unresponsiveness  with  Gm 
3;5,13,14/Gm  3;5,13,14  [Is(+)/Is(+)]  and  responsiveness  with  Gm  1,17;21/Gm 
3;5,13,14  [Ir(+)/Is(+)].  (Studies in mice have shown that although both Ir and Is 
genes  are  dominant  in  nature,  in  Ir/Is  heterozygotes  responder  phenotypes  are 
generally dominant over suppressor phenotypes.) If either of the above explanations 
were  accepted,  then  it  would  follow that  Gm  1,17;21 should  be  associated  with 
responsiveness to OSAA. Although none of the three patients in this study who were 
positive  for Gm  1,17;21  responded  to  OSAA,  the  frequency of this  phenotype in 
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be  studied  to  determine  conclusively  whether  this  phenotype  is  associated  with 
responsiveness  or unresponsiveness  to OSAA.  It  would  also be of interest  to study 
household contacts of osteosarcoma patients,  because in this group the incidence of 
antibodies to OSAA is much higher (over 25%)  than in noncontaets. 
Finally, the interactive effect of Ig allotype-linked and MHC-linked  genes, as has 
been demonstrated  for susceptibility to experimental  myasthenia gravis in mice (22) 
and for autoimmune chronic active hepatitis  (23) and immune responses to bacterial 
antigens in man  (12), may occur in osteosarcoma as well.  In future studies, we plan 
to analyze both HLA antigens and Gm allotypes in a  larger population of osteosar- 
coma  patients,  to  determine  whether  there  is  any  interactive  effect  of these  two 
unlinked  genetic  systems  on  the  pathogenesis  of  osteosarcoma  and  on  immune 
responses to OSAA. This report is the first description of a strong association between 
immune responsiveness to a  human cancer and Ig allotypes. 
Summary 
Serum samples from 50 Caucasian patients with osteosarcoma were tested for the 
presence  of antibodies  to  osteosarcoma-associated  antigens  (OSAA)  and  typed  for 
nine Gm markers.  A  highly significant association was found between Gm 3;5,13,14 
and unresponsiveness to OSAA, and between Gm 1,3,17;5,13,14,21  and responsiveness 
to  OSAA.  These  results  suggest  the  existence  of complementary  immune  response 
genes which in the heterozygous condition permit a  response to OSAA. 
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